title: The usefulness and scientific accuracy of private sector Arabic language patient drug information leaflets.
abstract: BACKGROUND
  Inadequate access to useful scientifically accurate patient information is a major cause of the inappropriate use of drugs resulting in serious personal injury and related costs to the health care system. The definition of useful scientifically accurate patient information for prescription drugs was accepted by the US Secretary of the Department of Health and Human Services in 1996 as that derived from or consistent with the US FDA approved professional product label for a drug. Previous quality content studies found that English language patient drug information leaflets distributed by US pharmacies failed to meet minimum criteria defining useful and scientifically accurate information.
  
  
  RESULTS
  Evaluation forms containing the explicit elements that define useful scientifically accurate information for three drugs with known serious adverse drug reactions were created based on the current US FDA approved professional product labels. The Arabic language patient drug information leaflets for celecoxib, paroxetine, and lamotrigine were obtained locally and evaluated using a methodology similar to that used in previous quality content patient drug information studies in the US. The Arabic leaflets failed to meet the definition of useful scientifically accurate information. The celecoxib leaflet contained 30% of the required information and the paroxetine and lamotrigine leaflets contained 24% and 20%, respectively. There are several limitations to this study. The Arabic leaflets from only one commercial North American vendor were evaluated and the evaluation included a limited number of drugs. A larger study is necessary to be able to generalize these results.
  
  
  CONCLUSIONS
  The study results are consistent with those of previous quality content studies of commercially available English patient drug information leaflets. The results have important implications for patients as access to a reliable source of drug information may prevent harm or limit the suffering from serious adverse drug reactions.
authors: 1201 North Shore Blvd. Burlington, Ontario, Canada L7S 1Z5.
authors: Sana R
authors: SR
authors: Sukkari
authors: Abdullah S
authors: AS
authors: Al Humaidan
authors: Larry D
authors: LD
authors: Sasich
keywords: Arabic; Drug information; Keystone criteria; Patient; Patient drug information; Patient information leaflet
references: Food Drug Law J. 1999;54(4):489-518
references: 11824450
references: BMJ. 2011 Jun 30;342:d4151
references: 21724544
references: Am J Health Syst Pharm. 2007 Jun 1;64(11):1142
references: 17519452
references: J Am Pharm Assoc (2003). 2005 Jul-Aug;45(4):443-51
references: 16128499
references: Arch Intern Med. 2010 Aug 9;170(15):1317-24
references: 20696955
references: N Engl J Med. 2011 Nov 24;365(21):2002-12
references: 22111719
references: J Am Pharm Assoc (2003). 2003 May-Jun;43(3):383-93
references: 12836789
references: Int J Technol Assess Health Care. 1993 Spring;9(2):238-50
references: 8458703
references: J Am Pharm Assoc (2003). 2007 Nov-Dec;47(6):717-24
references: 18032134